Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock

Posted by Francis Steltz on Sep 5th, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the transaction, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Trading Up 0.1%

Kymera Therapeutics stock opened at $117.39 on Friday. The firm has a 50 day moving average of $114.16 and a 200 day moving average of $94.90. The firm has a market capitalization of $9.76 billion, a price-to-earnings ratio of -36.23 and a beta of 1.96. Kymera Therapeutics, Inc. has a 12-month low of $42.22 and a 12-month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company’s revenue was up 465.2% on a year-over-year basis. During the same period last year, the firm posted ($0.95) EPS. On average, analysts predict that Kymera Therapeutics, Inc. will post -3.78 EPS for the current year.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in shares of Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after buying an additional 98 shares in the last quarter. US Bancorp DE raised its position in Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares during the period. Proficio Capital Partners LLC lifted its holdings in Kymera Therapeutics by 1.8% during the second quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company’s stock valued at $1,267,000 after purchasing an additional 200 shares in the last quarter. Glenmede Trust Co. NA grew its position in shares of Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after purchasing an additional 235 shares during the period. Finally, Cetera Investment Advisers increased its stake in shares of Kymera Therapeutics by 7.5% during the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after purchasing an additional 252 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently issued reports on KYMR shares. Canaccord Genuity Group increased their price objective on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. Wells Fargo & Company upped their price objective on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Bank of America upped their price target on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Citigroup reissued a “buy” rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. Finally, Guggenheim increased their target price on Kymera Therapeutics from $135.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $128.70.

View Our Latest Research Report on Kymera Therapeutics

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.